NCT07303465招募中2 期
A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ranok Therapeutics (Hangzhou) Co., Ltd.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年10月14日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- PFS
研究概览
简要总结
This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up.
- •Male and female subjects aged 18-75 years (including 18 and 75 years).
- •Pancreatic ductal adenocarcinoma confirmed by pathology (histology) or cytology.
- •At the time of study enrollment, according to the solid tumor efficacy evaluation criteria (RECIST1.1), imaging diagnosis had at least one measurable lesion .
- •Presence of a KRAS G12D mutation.
- •Physical condition score ECOG score 0-1 points.
- •Expected survival ≥ 12 weeks.
- •Have adequate hematologic and end-organ function, with laboratory test results within required parameters within 7 days prior to the first dose.
- •Fertile female subjects and male subjects whose partners are women of reproductive age must agree to comply with the contraceptive requirement from the time of signing the informed consent until 6 months after the final administration of the trial drug.Fertile female subjects must undergo a serum pregnancy test within 7 days before the first dose, and the result is negative; And must be non-lactating.
排除标准
- •Diagnosed with other pathological types of pancreatic tumors;
- •Presence of uncontrolled symptomatic central nervous system metastases; including leptomeningeal metastasis, spinal cord metastasis, or brainstem metastasis.
- •Presence of symptomatic, moderate or greater fluid accumulation in serous cavities (e.g., pleural effusion, ascites, pericardial effusion) which either necessitates therapeutic intervention or is judged by the investigator to make the patient ineligible.
- •Clinical condition with an acute and significant decline, including, but not limited to, a decrease in ECOG performance status to >1 within 72 hours prior to the baseline visit and initiation of study treatment, a weight loss of ≥10% during the screening period, or a BMI <18.0 kg/m²
- •Except for certain circumstances, a history of malignant tumors other than the inclusion diagnosis within 2 years prior to the first administration of the drug;
- •History of known severe or uncontrolled cardiovascular or cerebrovascular disease that requires treatment.
- •The patient had previously used KRAS inhibitors or pan-KRAS inhibitors therapy.
- •Received systemic anti-tumor therapy prior to the first dose, or received Chinese herbal preparations with clear anti-pancreatic tumor indications within 2 weeks before the first dose.
- •Having received other investigational drugs or therapies not yet approved for marketing prior to the first dose, with the interval from the last administration or treatment being less than 4 weeks or 5 half-lives (whichever is shorter).
- •Having undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose, or requiring elective surgery during the trial period.
- •The presence of severe non-healing wounds, ulcers, fractures, etc., within 4 weeks prior to the first dose.
- •Severe infection occurred within 4 weeks prior to the first dose, including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia; presence of systemic active infection within 2 weeks prior to the first dose requiring systemic anti-infective therapy.
- •Presence of active tuberculosis infection at the time of screening.
- •Positive for hepatitis B surface antigen (HBsAg) at screening with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 2000 IU/mL or 10⁴ copies/mL (however, subjects can be enrolled if their HBV-DNA is <2000 IU/mL or 10⁴ copies/mL after antiviral therapy).
- •Positive for hepatitis C antibody (HCV-Ab) and positive for hepatitis C virus (HCV) ribonucleic acid (RNA) at screening.
- •Known infection with human immunodeficiency virus (HIV) or active Treponema pallidum, except under certain circumstances.
- •Presence of any toxicity from previous antitumor therapies that has not recovered to Grade ≤
- •Other situations that the researchers believe should not be included.
研究组 & 干预措施
RNK08954
Experimental
干预措施: RNK08954 (Drug)
结局指标
主要结局
PFS
时间窗: up to 2 years
Progression-free survival (PFS) is assessed by investigators using RECIST 1.1 criteria.
次要结局
- AUC(Up to 12 months)
- ORR(up to 2 years)
- DOR(up to 2 years)
- DCR(Up to 2 years)
- AEs(Up to 2 years)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
JSKN022 in Subjects With Advanced Malignant Solid TumorsNCT07292402Jiangsu Alphamab Biopharmaceuticals Co., Ltd225
进行中（未招募）
1 期
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid TumorsNCT07274449The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6
招募中
1 期
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaNCT07283679M.D. Anderson Cancer Center30
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
招募中
1 期
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsBiliary Tract CarcinomaPleural MesotheliomaBladder CancerMesotheliomaPancreatic CancerNCT07277413IDEAYA Biosciences260